Moleculent raised $20M in funding, led by Rubicon Healthcare Partners. The company aims to support its expansion and accelerate commercial operations in the U.S.
Amount Raised
$20 Million
Round Type
Funding Round
StockholmBiotechnologyHealth CareInvestors
Description
Moleculent, a Stockholm-based life sciences technology company, raised $20M in funding. The round was led by Rubicon Healthcare Partners, with participation from ARCH Venture Partners, Eir Ventures, and other existing investors. The company intends to use the funds to support its expansion and drive commercial operations in the United States. Moleculent is developing a platform to measure cell–cell interactions in clinical tissue at scale.
Quick answer
Moleculent AB raised $20 Million in a Funding Round round, dated April 30, 2026. Investors: Eir Ventures, ARCH Venture Partners and Rubicon Healthcare Partners. Moleculent AB is based in Stockholm, Stockholm County, Sweden.
- How much did Moleculent AB raise?
- Moleculent AB raised $20 Million in a Funding Round round on April 30, 2026.
- Who invested in Moleculent AB?
- Eir Ventures, ARCH Venture Partners and Rubicon Healthcare Partners are named as investors in this round.
- What does Moleculent AB do?
- Moleculent is a company on a mission to develop advanced technology-enabled products that leverage new insights into the molecular foundation of human biology.
- Where is Moleculent AB based and how big is it?
- Moleculent AB is based in Stockholm, Stockholm County, Sweden. Fundz records about 64 employees.
- Who are the decision-makers at Moleculent AB?
- Fundz holds 2 contacts at Moleculent AB, including the Founder and CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Moleculent AB that raised within 45 days of this round, from Fundz verified event records.
- CEL-SCI Corporation raised $2.5M (Post-IPO Equity) on June 14, 2026.
- YouLabs raised $2.6M (Seed) on June 12, 2026.
- Evom AI raised an undisclosed amount (Seed) on June 12, 2026.
- ThruFlo Endovascular raised an undisclosed amount (Seed) on June 11, 2026.
- 4baseCare raised $4M (Series B) on June 11, 2026.
- Promedius raised $17M (Pre-Seed) on June 10, 2026.
Who to call at Moleculent AB, and when
A new round usually means Moleculent AB is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Moleculent AB raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Moleculent AB, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Moleculent AB. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Moleculent AB raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Moleculent AB raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.